Clinical Trial: High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: High Intensity Focused Ultrasound (HIFU) for Parathyroid Adenoma

Brief Summary: This study aims to determine whether HIFU treatment is a safe and effective alternative to an operation to remove all or part of the affected gland. The objective is to achieve biochemical cure (assessed by normal calcium level in the blood at six weeks, six months and one year after therapy) without affecting the patient's voice or ability to swallow.

Detailed Summary:

Primary hyperparathyroidism is a common endocrine condition in which one or more of the four parathyroid glands in the neck releases too much parathyroid hormone (PTH). this leads to excess calcium in the blood and if untreated it can cause osteoporosis, kidney stone formation, deterioration of kidney function and disturbance in heart rhythm. Surgery to remove all or part of the affected gland(s) is expected to cure 95% of such patients. In current practice all such patients undergo localisation techniques using sestamibi scanning and neck ultrasonography to demonstrate the position of the enlarged/overactive parathyroid gland. These radiological tests are positive in some two thirds of patients, who can be operated through a minimally invasive procedure focused on the exact localisation pinpointed by the scans.

This study uses a procedure that does not require a surgical incision. Precise imaging of the parathyroid glands allows the exact position of the tumour to be found from outside the body. A High Intensity Focused Ultrasound beam produces heat, but only in a small specific area. Exact positioning of the ultrasound beam targets the tumour cells and kills them without harming the surrounding healthy tissues.


Sponsor: Oxford University Hospitals NHS Trust

Current Primary Outcome: Eucalcaemia [ Time Frame: 12 months post-treatment ]

Calcium in the blood is measured from venepuncture


Original Primary Outcome: Eucalcaemia [ Time Frame: 12 months post-treatment ]

Current Secondary Outcome:

  • Eucalcaemia [ Time Frame: Six weeks post-treatment.Six month data were also intended to be reported, however, six month data were not analyzed because only one subject was entered and this subject was withdrawn from the study before six months after treatment. ]
    Ca in plasma
  • Voice Morbidity [ Time Frame: Up to one year post-treatment ]
    Voice Handicap Index. 30 questions rated on a five point scale from 'never' to 'always' and an overall score from 1 'normal' to 10 'severely impaired'


Original Secondary Outcome:

  • Eucalcaemia [ Time Frame: 6 weeks and 6 months post-treatment ]
  • Voice Morbidity [ Time Frame: Up to one year post-treatment ]
  • Swallowing Morbidity [ Time Frame: Up to one year post-treatment ]
  • Parathyroid symptom score [ Time Frame: Up to one year post-treatment ]
    Pasieka's parathyroid sympton score


Information By: Oxford University Hospitals NHS Trust

Dates:
Date Received: February 7, 2011
Date Started: April 2011
Date Completion:
Last Updated: July 21, 2014
Last Verified: July 2014